Immuneering reports 43% ORR in first-line pancreatic combo; plans new trials in 2025

Immuneering Corp

IMM-1-104 + mGnP in 1L pancreatic: 1 complete response, 2 partial response (43% ORR), 86% DCR among 7 evaluable patients.
IMM-1-104 + mFFX in 1L pancreatic: all 4 patients had tumor shrinkage; 1 partial response with 100% target lesion reduction.
IMM-1-104 monotherapy in 2L pancreatic: 11 of 21 evaluable patients achieved disease control; 1 partial response with 67% reduction.
IMM-6-415 Phase 1 PK/PD: up to 77% pERK inhibition; generally well tolerated with no dose-limiting toxicities.
Additional Phase 2a data expected Q2 2025; plans to launch arms in melanoma and NSCLC with combinations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.